TIDMSENS
RNS Number : 6740R
Sensyne Health PLC
30 October 2019
Result of AGM
Oxford, UK; 30 October 2019: Sensyne Health plc (LSE: SENS)
("Company"), the British clinical AI technology company, announces
that all resolutions put to its Annual General Meeting (the "AGM")
held today were passed. Resolution 10 was withdrawn by the Company
following the decision of Charles Swingland not to seek re-election
as a Director at the AGM.
For information, full details of the votes received were as
follows:
Resolution Number For Against Withheld Total Vote
No. of % No. of % No. of Votes No. of
Votes Votes Votes
---------- ------ ---------- ----- ------------ ----------
1. Receive the Annual
report and accounts
for the Company 83,669,303 100.00 250 0.00 7,300,000 83,669,553
---------- ------ ---------- ----- ------------ ----------
2. Approve the Directors'
Remuneration Report 59,657,635 71.30 24,011,918 28.70 7,300,000 83,669,553
---------- ------ ---------- ----- ------------ ----------
3. Re-elect Lord
(Paul) Drayson as
a Director 49,183,591 100.00 2,000 0.00 15,270 49,185,591
---------- ------ ---------- ----- ------------ ----------
4. Re-elect Andrew
Gilbert as a Director 75,420,438 90.16 8,233,865 9.84 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
5. Re-elect Dr Vishal
Gulati as a Director 83,654,303 100.00 0 0.00 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
6. Re-elect Mary
Hardy as a Director 83,654,303 100.00 0 0.00 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
7. Re-elect Lorimer
Headley as a Director 83,654,303 100.00 0 0.00 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
8. Re-elect Dr Annalisa
Jenkins as a Director 90,954,303 100.00 0 0.00 15,250 90,954,303
---------- ------ ---------- ----- ------------ ----------
9. Re-elect Sir Bruce
Keogh as a Director 83,654,303 100.00 0 0.00 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
10. Re-elect Charles RESOLUTION WITHDRAWN
Swingland as a Director
---------------------------------------------------------------
11. Elect Professor
Lionel Tarassenko
as a Director 83,497,695 99.81 156,608 0.19 7,315,250 83,654,303
---------- ------ ---------- ----- ------------ ----------
12. Re-appoint PricewaterhouseCoopers
LLP as auditors of
the Company 83,669,303 100.00 0 0.00 7,300,250 83,669,303
---------- ------ ---------- ----- ------------ ----------
13. Authorise the
Audit & Risk Committee
of the Company 83,669,303 100.00 0 0.00 7,300,250 83,669,303
---------- ------ ---------- ----- ------------ ----------
14. Directors' authority
to allot shares 80,209,253 100.00 0 0.00 10,760,300 80,209,253
---------- ------ ---------- ----- ------------ ----------
15. Disapplication
of pre-emption rights* 80,209,253 100.00 0 0.00 10,760,300 80,209,253
---------- ------ ---------- ----- ------------ ----------
16. Disapplication
of pre-emption rights
Addition* 80,206,753 100.00 0 0.00 10,762,800 80,206,753
---------- ------ ---------- ----- ------------ ----------
17. Authority to
purchase own shares* 80,209,253 100.00 0 0.00 10,760,300 80,209,253
---------- ------ ---------- ----- ------------ ----------
18. Rule 9 Waiver
- Relating to Buyback
Authority 25,056,044 65.18 13,384,497 34.82 10,760,320 38,440,541
---------- ------ ---------- ----- ------------ ----------
19. Rule 9 Waiver
- Relating to the
Exercise of Options 25,053,544 65.17 13,386,997 34.83 10,760,320 38,440,541
---------- ------ ---------- ----- ------------ ----------
Notes:
1. Resolution 10 was withdrawn as Charles Swingland decided not
to seek re-election as a Director at the AGM.
2. A vote withheld is not a vote in law and is not counted in
calculating votes for or against a resolution.
3. The total number of ordinary shares in issue as at 30 October
2019 was 128,571,514 (128,571,514 with voting rights).
* Special Resolution requiring a 75% majority.
The Board notes that more than 20% of shareholders voted against
resolution 2 on approving the Directors' Remuneration Report. As
noted in the Company's announcement of 22 October 2019 headed
Remuneration Policy and Corporate Governance Update, a number of
actions have already been implemented addressing the issue of
remuneration. The Company has withdrawn the remuneration policy in
relation to the CEO for the period from 1st May 2019 to 30th April
2020 and the Remuneration Committee will also undertake discussions
with shareholders to determine a new Remuneration Policy for the
CEO applicable to the period from 1st May 2019 until 30th April
2020 that has their support.
-ENDS-
For more information please contact:
+44 (0) 330 058
Sensyne Health (www.sensynehealth.com) 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a healthcare technology company that
creates value from accelerating the discovery and development of
new medicines and improving patient care through the analysis of
real-world evidence from large databases of anonymised patient data
in collaboration with NHS Trusts. These anonymised patient data are
ethically sourced in that any analysis of anonymised patient data
(and hence the Company's access to it) must be pre-approved for
each programme on a case-by-case basis by the relevant NHS Trusts.
This is to ensure that the purpose of the anonymisation and the
proposed analysis are subject to appropriate ethical oversight and
information governance, including conformance with NHS principles,
UK data protection law and applicable regulatory guidance. Sensyne
Health is an early signatory to the Department of Health and Social
Care's 'Initial Code of Conduct for data-driven health and care
technology.
Sensyne Health is listed on the AIM Market of the London Stock
Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RAGCKKDBQBDDAKN
(END) Dow Jones Newswires
October 30, 2019 10:29 ET (14:29 GMT)
Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Apr 2023 a Apr 2024